Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
The review found no eligible studies for this question.
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy probably leads to lower para‐aortic lymph node recurrence compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy showed no clear difference in progression‐free survival compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy showed no clear difference in adverse events compared with pelvic radiotherapy (moderate certainty).
Extended‐field radiotherapy probably leads to lower overall survival compared with pelvic chemoradiotherapy (moderate certainty).
Extended‐field radiotherapy may leads to lower para‐aortic lymph node recurrence compared with pelvic chemoradiotherapy (low certainty).
Extended‐field radiotherapy probably leads to lower progression‐free survival compared with pelvic chemoradiotherapy (moderate certainty).
Extended‐field radiotherapy probably leads to lower acute adverse events compared with pelvic chemoradiotherapy (moderate certainty).
Extended‐field radiotherapy showed no clear difference in late adverse events compared with pelvic chemoradiotherapy (moderate certainty).
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).